Renal and Cardiac Effects of DPP-4 Inhibitors from Preclinical Development to Clinical Research
出版年份 2012 全文链接
标题
Renal and Cardiac Effects of DPP-4 Inhibitors from Preclinical Development to Clinical Research
作者
关键词
-
出版物
KIDNEY & BLOOD PRESSURE RESEARCH
Volume 36, Issue 1, Pages 65-84
出版商
S. Karger AG
发表日期
2012-08-28
DOI
10.1159/000339028
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?
- (2014) JM Lestner et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
- (2012) Odd Johansen et al. Cardiovascular Diabetology
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects
- (2011) C. G. Patel et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects
- (2011) A. Karim et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
- (2011) Lyubov Chaykovska et al. PLoS One
- Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice
- (2010) A. D. Dobrian et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts
- (2010) Dongsheng Zhang et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats
- (2010) SM Gardiner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats
- (2010) Barbara Huisamen et al. CARDIOVASCULAR DRUGS AND THERAPY
- Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome
- (2010) David S Tofovic et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
- (2010) M. Sauve et al. DIABETES
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis
- (2010) Hans D. Theiss et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats
- (2010) Bruna PM Pacheco et al. JOURNAL OF HYPERTENSION
- Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
- (2010) Liliana Ferreira et al. MEDIATORS OF INFLAMMATION
- GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
- (2010) Hui-Chun Ku et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury
- (2010) G. Stokman et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes
- (2010) Jitendra Vaghasiya et al. REGULATORY PEPTIDES
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats
- (2009) Silke Retlich et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
- (2009) Marc-Michael Zaruba et al. Cell Stem Cell
- Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
- (2009) E. U. Graefe-Mody et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
- (2009) T. Heise et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections
- (2009) A. Fura et al. DRUG METABOLISM AND DISPOSITION
- Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead
- (2009) Rigas Kalaitzidis et al. Journal of Clinical Hypertension
- Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants
- (2009) Aziz Karim et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
- (2009) Holger Fuchs et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Therapeutic targets to reduce cardiovascular disease in type 2 diabetes
- (2009) Cyrus DeSouza et al. NATURE REVIEWS DRUG DISCOVERY
- In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma
- (2008) Marco M. Jost et al. BIOCHEMICAL PHARMACOLOGY
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
- (2008) R CHRISTOPHER et al. CLINICAL THERAPEUTICS
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
- (2008) P COVINGTON et al. CLINICAL THERAPEUTICS
- Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use
- (2008) D. P. Kao et al. DIABETIC MEDICINE
- Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
- (2008) H. He et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
- (2008) Bumsup Lee et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Sitagliptin Augments Sympathetic Enhancement of the Renovascular Effects of Angiotensin II in Genetic Hypertension
- (2008) Edwin K. Jackson et al. HYPERTENSION
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
- (2008) S. Hüttner et al. JOURNAL OF CLINICAL PHARMACOLOGY
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
- EFFECTS OF DIPEPTIDYL PEPTIDASE IV INHIBITION ON ARTERIAL BLOOD PRESSURE
- (2007) Edwin K Jackson et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started